Cancer Immunotherapy Market Size, Share, Growth Analysis, By Type (Monoclonal Antibodies, Cancer Vaccines), By Application (Lung Cancer, Breast Cancer), By Route of Administration (Intravenous (IV), Intramuscular), By End User, By Region - Industry Forecast 2026-2033

Personalized immunotherapy is becoming popular as countries globally provide funding for precision medicine initiatives. The United States National Cancer Institute provided more than USD 45 million in 2024 for immunotherapy research in the area of genomics that has allowed personalized treatments to improve treatment effectiveness and reduce toxicity. The advancements needed to create personalized immunotherapy treatment options will improve care for patients internationally.

The market for cancer immunotherapy is projected to have a compound annual growth rate of 9.0% from 2025 to 2032, with the growth drivers including the increase in cancer incidence, technology improvements and growing demand for targeted immuno-oncology therapies.

The main types are Monoclonal Antibodies, Cancer Vaccines, Checkpoint Inhibitors and Immunomodulators. Each has a different mechanism of enhancing the immune system's capabilities to recognize and destroy cancer cells.

Monoclonal antibodies target cancer cells with higher specificity while largely sparing normal tissues. Monoclonal antibodies are the fastest growing segment of cancer immunotherapy due to their specificity and the advancement of breakthroughs spearheaded by the government, such as Amgen's Imdelltra.

Cancer vaccines provide the means to stimulate the immune system to recognize and attack cancer cells. Many initiatives are backed to support cancer vaccine developments, like the NHS Cancer Vaccine Launch Pad in the UK, and highlight the emergence of cancer vaccines as part of advanced-stage cancer treatments - melanoma in particular.

Immunotherapy is a conventional treatment across all lung, breast, colorectal, melanoma, prostate, and hematologic cancers, especially when conventional treatments show less effect or have limited efficacy for patients.

The main end-users are Hospitals & Clinics, Cancer Research Centers, and Others. While hospitals and research institutions play the largest role in providing treatment, both groups play a vital role in advancing innovation in cancer therapy with immunotherapy.

Cancer research centers are advancing beyond shared intellectual property, through clinical trials, R&D and strategies for collaboration, all supported by public-private funding sources. Their research and development encourages next generation therapies, such as CAR-T, and innovative personalized cancer vaccines.

Typically, governments are able to hasten drug approvals through regulatory agencies like the FDA and EMA and their requests for immunotherapies and funding for clinical trials, which improves access and accelerates the market by eliminating barriers through the use of regulations and funding grants.

North America is a leader in this sector as it is home to significant healthcare infrastructure, high levels of investment in R&D, and incentives and support from regulators. The United States and its numerous biotech hubs and approvals from the FDA, especially with Keytruda and its recent expansion, is a major contributing factor to the region’s dominance.

Even though immunotherapy offers significant market growth potential, high costs for therapies to patients, particularly with complicated CAR-T medications, and limited access for low income areas, will slow universal acceptance and slow the growth of the global immunotherapy market.